PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age
Frontiers in Oncology · 27.10.2025 · 15
DOI: 10.3389/fonc.2025.1676414 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 27.10.2025. Verfasst von Jiale Cai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, China. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Graduate Research and Innovation Projects of Jiangsu Province.
Abstract (Originalsprache)
Proteolysis Targeting Chimera (PROTAC) is a heterobifunctional molecule comprising three core components: a target protein ligand (typically a small-molecule inhibitor), a linker, and an E3 ubiquitin ligase ligand. By harnessing the specificity of the endogenous ubiquitin-proteasome system (UPS), PROTACs induce ubiquitination and subsequent degradation of target proteins. This technology constitutes an advanced therapeutic strategy for selective protein degradation, thereby expanding the horizons of drug design. Its significant therapeutic potential extends to treating cancers, viral infections (e.g., HIV and SARS-CoV-2), and chronic diseases. Recent clinical studies on compounds such as ARV-471 have yielded encouraging results, validating the efficacy of this approach. Over the past decade, PROTAC technology has garnered widespread attention in biomedicine for its promise in developing novel targeted therapies. This review will elucidate the broad therapeutic prospects and future challenges of PROTACs by detailing their mechanism of action, recent advances, progress in targeted therapy research, and current clinical trial landscape.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, China.
- Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, Yangzhou University, Yangzhou, Jiangsu, China.
- Department of Gastrointestinal Surgery, Jiangdu People's Hospital Afliated to Yangzhou University, Yangzhou, China.
Förderung
- National Natural Science Foundation of China
- Graduate Research and Innovation Projects of Jiangsu Province
Zitieren
APA
Cai, J., Chen, C., Wang, J., Zhang, X., Cui, Y., Zhu, Q., & Sun, H. (2025). PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1676414
Vancouver
Cai J, Chen C, Wang J, Zhang X, Cui Y, Zhu Q, et al. PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1676414
BibTeX
@article{Cai2025,
author = {Cai, Jiale and Chen, Chen and Wang, Jiayue and Zhang, Xinmeng and Cui, Yuqiu and Zhu, Qunshan and Sun, Haibo},
title = {PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1676414}
}
EUVIMED